Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Quick Listen: Scrip's Five Must-Know Things

Executive Summary

Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharma industry.

A new bite-size podcast provides a brief audio tour around Scrip's Five Must-Know Things, starting off for the week ended 19 July.

This time we provide easy to digest updates around Operation Warp Speed, diversity in the biopharma industry, shifting commercial models, new results in psoriasis, and the future of cell and gene therapies.

Stories mentioned in this podcast:

(Also see "Operation Warp Speed Shortlist Not Decided Yet, Says Novavax" - Scrip, 15 Jun, 2020.)

(Also see "Leading A Diverse Company: Biopharma Executives Offer Ways Forward" - Scrip, 12 Jun, 2020.)

(Also see "Commercial Models Shifting As Pharma Mulls Digital-First Launches" - Scrip, 16 Jun, 2020.)

(Also see "Can UCB's Bimekizumab Go From Last To First In Psoriasis?" - Scrip, 15 Jun, 2020.)

(Also see "The Future Of Medicine: Cell And Gene Therapies Take The Lead" - Scrip, 11 Jun, 2020.)

 

 

 

 

 

Related Content

Topics

UsernamePublicRestriction

Register

MT142464

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel